Clinical Trial Program 2017/2018
ECWM-1 (https://clinicaltrials.gov/ct2/show/NCT01788020?term=ECWM-1&rank=1)
Study Design: Phase III, randomized, multicenter, international trial
Patients: treatment naive WM patients
Treatment: DRC versus Bortezomib-DRC
Status of the Study: Patient recruitment: closed (last patient in Sept 2018, n = 202)
Sponsor: University Hospital of Ulm, PI Christian Buske
ECWM-2 (https://clinicaltrials.gov/ct2/show/NCT03620903?term=ECWM-2&rank=1)
Study Design: Phase II, single arm, multicenter, international
Patients: treatment naive WM patients
Treatment: Bortezomib-Rituximab-Ibrutinib
Status of the Study: not yet recruiting (first patient in planned Q1 2019, n= 53)
Sponsor: University Hospital of Ulm, PI Christian Buske
ECWM-3 (CZAR-1)
Study Design: Phase III, randomized, multicenter, international trial
Patients: treatment naive and relapsed WM patients
Treatment: Carfilzomib/Ibrutinib versus Ibrutinib
Status of the Study: not yet recruiting (first patient in planned Q2 2019, n= 53)
Sponsor: University Hospital of Ulm, PI Christian Buske
HOVON124/ECWM-R2 trial
Study Design: Phase II, single arm, multicenter, European trial
Patients: relapsed WM patients
Treatment: Ixazomib, rituximab and dexamethasone (IRD)
Status of the Study: recruiting
Sponsor: University Hospital Amsterdam, PI Marie Jose Kersten
ECWM-R3 (Remodel)
Study Design: Phase II, single arm, multicenter, French trial for treatment naive WM patients
Patients: relapsed WM patients
Treatment: Idelalisib-Obinutuzumab
Status of the Study: fully recruited
Sponsor: Tour, France